Nanosive

Nanosive is a biotechnology company focused on advancing the delivery of genetic medicines through its proprietary non-viral platform. Spun out from the University of Nottingham, the company develops synthetic nanoparticle systems designed to overcome the limitations of traditional viral vectors and lipid nanoparticles. Their technology facilitates the efficient intracellular delivery of various payloads, including mRNA, pDNA, and CRISPR-Cas9, with a focus on improving safety, stability, and scalability. Nanosive's platform is particularly optimized for challenging applications such as pulmonary delivery and systemic targeting of rare diseases. By providing a versatile and customizable delivery solution, the company aims to accelerate the development of next-generation gene and cell therapies.